.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a mean consequence of 11 months, individuals along with metastatic stomach cysts that acquired biomarker-matched therapies based on spreading growth DNA profiling showed a better professional benefit than those acquiring unmatched therapy.